10000 documents

Innate Immunity and Viral Infection in Asthma

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Monica Kraft · UNIVERSITY OF ARIZONA · 2022 · $1,431,641 — In this AADCRC program renewal, we will focus on three critical and understudied innate immune factors and how they impact viral infections in asthma: the anionic phospholipids of surfactant (palmitoyl- oleoyl-phosphatidylglycerol, POPG, and phosphatidylinositol, PI), Toll interacting protein (Tolli…

Comparative, single-cell analysis of COVID-19 and other respiratory diseases

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Alexander Minchev Tsankov · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $126,750 — PROJECT SUMMARY COVID-19 disease, caused by the novel coronavirus SARS-CoV-2, is a global health threat due to its rapid spread, morbidity, and mortality. It is estimated that at least 25% of severe COVID-19 disease survivors experience persistent respiratory complications. This underscores the need…

Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered vein-chip

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

JOHN P COOKE · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $665,322 — ABSTRACT Determinants of COVID19-induced venous thrombosis and targeted therapy assessed with bioengineered Vein-Chip Challenge: Increasing evidence shows that SARS-CoV-2, which is the novel coronavirus that causes COVID- 19, is able to trigger the formation of blood clots within the veins of patien…

Elucidating the role of SERINC5 in SARS-CoV-2 infection

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Spyridon Stavrou · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2022 · $239,250 — A viral pathogen associated with severe pneumonia was recently identified as the cause of a global pandemic that has resulted in the death of over two million people. This viral pathogen was later classified as a coronavirus that was subsequently named Severe Acute Respiratory Syndrome Coronavirus 2…

Defining the Impact of Per/Polyfluoroalkyl Substance Exposure on Susceptibility to SARS-CoV-2 Infection and Disease

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Florian Douam · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $201,700 — Project Summary We are in the midst of an unprecedented, modern pandemic as a result of the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019. SARS-CoV-2 is one of three known coronaviruses that can replicate in the lower respiratory tract and cause pneumoni…

Regulation of inflammatory gene expression during SARS2 infection

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Ivan Marazzi · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $794,868 — PROJECT SUMMARY Infection causes inflammation, which contributes to pathogen clearance and survival of the host organism. However, failure to regulate the inflammatory response can often lead to multiple organ damage and lethality for the host. In the current COVID-19 pandemic caused by the severe a…

Targeting Functional RNA Elements in the SARS-CoV-2 Genome

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

John Schneekloth · DIVISION OF BASIC SCIENCES - NCI · 2022 · $324,711 — Traditional drug screening strategies are based on targeting coronavirus-related proteins (e.g., RdRp, Mpro, and 3CLpro) and receptors (e.g. ACE2). In addition to virus-coded proteins, RNA structures within the SARS-CoV-2 genome also regulate essential functions and are potentially at…

Biomarker Investigations for Clinical Trials

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Liang Cao · DIVISION OF BASIC SCIENCES - NCI · 2022 · $822,832 — Related to the specific biomarker goals above, we conducted various studies to support biomarker driven early-stage drug development: 1. Application of new or novel biomarkers in early-stage trials of highly unique therapeutic agents. A) We supported correlative marker investigations …

Development of ALG-097431 as a broad-spectrum 3CL pro inhibitor

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Julian A Symons · HACKENSACK UNIVERSITY MEDICAL CENTER · 2022 · $4,228,031 — Project Summary/Abstract: Development of ALG-097431 as a Broad-Spectrum SARS-CoV-2 3CLpro Inhibitor Inhibition of viral proteases with small molecule drugs is a proven successful therapeutic approach and is currently used for the treatment of HCV and HIV infection. The SARS-CoV-2 main, 3-chymotrypsi…

Structure-guided immunogens to elicit pan-coronavirus B cell responses

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Aaron Gregory Schmidt · WASHINGTON UNIVERSITY · 2022 · $1,934,136 — Project Summary The global pandemic caused by Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2) coronavirus (CoV) has highlighted the need to develop next-generation viral vaccines that offer protection against future Sarbecoviruses and Merbecoviruses of concern. One approach is to implement st…

Project-002

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Noha Shawky · UNIVERSITY OF MISSISSIPPI MED CTR · 2022 · $268,835 — Polycystic ovary syndrome (PCOS), the most common endocrine disorder in young women, is characterized by hyperandrogenemia and metabolic dysfunction. PCOS women who become pregnant may have offspring born with low birth weight (LBW), associated with increased risk for cardiovascular (CV) disease (…

Experimental and natural SARS-CoV-2 infection of the human pancreas

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

DIRK HOMANN · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2022 · $418,419 — ABSTRACT The possibility that infection with SARS-CoV-2 may trigger diabetes emerged as a concern in mid 2020. We have addressed this issue by developing a research roadmap that identified complementary areas of investigation according to several broad topics in the realm of relevant basic biomedica…

Pathogenesis of myalgia and fatigue after SARS-CoV-2 infection

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Sachiko Homma · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $270,903 — PROJECT SUMMARY As the COVID-19 pandemic continues, managing post COVID-19 long-haul symptoms have become the next level challenge. Persistent skeletal muscle aches (myalgia) and fatigue are among the most common symptoms reported by COVID-19 long haulers who have symptoms beyond 20 weeks. The myalg…

Cerebral vascular pathology of COVID-19

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Michal Toborek · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · 2022 · $148,376 — ABSTRACT COVID-19, which is caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), has resulted in devastating morbidity and mortality worldwide due to lethal pneumonia and respiratory distress. In addition, the central nervous system (CNS) is well documented to be a target of SARS…

Novel treatment for respiratory distress due to SARS-CoV2 infection

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Cynthia Ann Derdeyn · EMORY UNIVERSITY · 2022 · $195,625 — SUMMARY Clinical sequelae of COVID-19 patients include not only acute respiratory distress syndrome (ARDS), but also often acute kidney injury and heart failure. These pathologies share endothelial activation as a common underlying early response to injury, and endothelial cells express high levels …

Impact of SARS-CoV-2 mediated salivary gland dysfunction on secreted salivary antimicrobial peptides and the risk for oral opportunistic infections

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

MARY ANN Y JABRA-RIZK · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $231,750 — PROJECT SUMMARY Recently, individuals with COVID-19 were found to harbor replicating SARS-CoV-2 inside salivary epithelial cells resulting in inflammation, architectural distortion, and atrophy of minor and major salivary glands. We have previously demonstrated the importance of histatin-5, a secret…

Mechanisms for post-COVID pituitary damage

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Takako Araki · UNIVERSITY OF MINNESOTA · 2022 · $392,800 — PROJECT SUMMARY COVID-19–related extra-pulmonary damage is common and may even be observed in patients with mild COVID- 19 symptoms. There is an urgent and immediate need to establish optimal post-infection health care strategies for these patients, yet mechanisms underlying their appearance remain …

Lung delivery of novel ACE2 variants for COVID-19

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Jack Henkin · ANGIOTENSIN THERAPEUTICS, INC. · 2022 · $299,842 — Project Summary Systemically administered soluble native ACE2 is currently tested as a viral decoy to prevent SARS-CoV-2 cell entry in COVID-19 patients. This soluble ACE2 protein, however, has a short half-life and limited bioavailability in the lung, especially at the target sites for SARS-CoV-2 e…

De Novo Designed Protein Nanoparticle Agonists Targeting the Tie2 Receptor for the Treatment of ARDS and Sepsis in Patients with COVID-19

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

George Ueda · UNIVERSITY OF WASHINGTON · 2022 · $127,929 — Broader Impacts: The current COVID-19 outbreak is a global pandemic with over 45 million cases and 1,200,000 deaths officially reported. Epidemiological data emerging from Italy indicate that 40-96% of COVID- 19 patients admitted into the hospital develop ARDS and sepsis. Developing a functional tre…

Mutational Analysis of Tradeoffs between Receptor Affinity and Antibody Escape for SARS-CoV-2 Variants of Concern

NIH Pandemic-Era Grants · Pandemic Era Grants / 2022

Peter M Tessier · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $218,873 — Emerging SARS-CoV-2 variants are of broad interest because they may be more resistant to current vaccines and associated immune responses. Toward the long-term goal of understanding how receptor-binding domain (RBD) mutations impact transmissibility, it is critical to elucidate the impacts of RBD mu…